Estimated reading time: 7 minutes
Key Takeaways
- Helen of Troy shares plunged nearly 30 % in a single session, erasing about US$600 million in market value.
- Fourth-quarter results missed consensus by a wide margin, with a non-cash impairment driving a GAAP loss of US$19.65 per share.
- Rising Chinese tariffs and supply-chain costs shaved 420 bps from gross margin.
- Leverage has climbed to 4.4× EBITDA, prompting a halt to share buy-backs.
- Project Pegasus is behind schedule, capturing just US$19 million of targeted savings.
Table of contents
Share-Price Freefall
Helen of Troy (NASDAQ: HELE) endured what traders call a “capitulation day.” The stock opened at US$75.10—almost US$20 below the prior close—before skidding to an intraday low of US$69.85. Volume was three times the 90-day average, a classic sign of forced selling. Technical support evaporated as prices sliced through the 50- and 200-day moving averages, while an RSI of 21 screams oversold. Yet, as one desk strategist quipped, “You can’t chart your way out of a tariff problem.”
Quarterly Numbers at a Glance
Management had warned of headwinds, but few expected revenue to tumble 10.8 % to US$458 million or gross margin to shrink to 37.1 %. A US$442 million impairment tied to Beauty & Wellness pushed the operating line deep into the red. Adjusted EPS of US$0.41 was less than one-third of the US$1.60 Wall Street had pencilled in. The dismal print prompted outlets like GuruFocus to flag the quarter as among the worst in the consumer-goods space this season.
Segment Breakdown
- Home & Outdoor: Sales sank 14.5 % as retailers slashed orders and promoted aggressively, clipping margin by 310 bps.
- Beauty & Wellness: Revenue slipped 7.7 % with North American hair-appliance sell-in especially weak. Several pharmacy chains curtailed inventory, worsening the decline.
Key takeaway: Both divisions are contracting, but Beauty & Wellness also carries goodwill now flagged as fragile—raising the spectre of further write-downs.
Tariffs & Project Pegasus
Section 301 duties reinstated last year add 7–10 % to landed cost. Tariff expense was US$22.3 million this quarter, a 24 % jump year-on-year, and management admits duties carved 160 bps off gross margin. With U.S. trade policy on ice until after the election, relief looks unlikely.
Meanwhile, cost-saving programme Project Pegasus aims for US$75–85 million in annual savings by FY 2026 but has banked only US$19 million so far, citing labour shortages at the new Tennessee hub and IT glitches. Investors want faster execution—or at least credible milestones.
Balance Sheet & Cash Flow
Net debt sits at US$1.13 billion, translating to 4.4× trailing EBITDA—uncomfortably close to covenant limits. Interest coverage has fallen to 2.7× as floating-rate costs bite. Operating cash flow flipped to a negative US$37.4 million on higher receivables and accelerated supplier payments, pushing free cash flow to –US$50.2 million.
Management has paused buy-backs and M&A until leverage subsides below 3.5×, but mandatory amortisation of ~US$25 million per quarter keeps liquidity tight.
Valuation & Outlook
Post-crash, HELE trades at 7.9× forward EV/EBITDA versus a five-year median of 11×, and just 0.8× forward sales. Cheap? Perhaps, but as one analyst warns, “low multiples don’t rescue falling earnings.” Street models now assume low-single-digit revenue declines and margin compression to 9 % in FY 2025, pegging fair value near US$80–85—only modestly above the current mid-70s print.
Catalysts include timely completion of the Tennessee hub, potential tariff relief, or a non-core brand sale. Risks range from further impairments to macro-driven demand shocks. For now, the stock may be a value trap rather than a hidden gem.
FAQs
Why did Helen of Troy shares collapse so sharply?
A wide earnings miss, a large impairment charge, and renewed tariff pressure triggered a swift re-rating by the market.
How significant are tariffs to the company’s profitability?
Tariffs cost about US$22 million this quarter alone and shaved roughly 160 bps off gross margin, undermining competitiveness against peers with more diversified sourcing.
What is Project Pegasus and is it on track?
Project Pegasus is a multi-year efficiency drive targeting US$75–85 million in savings. Only US$19 million has been realised to date, so execution speed is under scrutiny.
Is the balance-sheet leverage manageable?
Net leverage of 4.4× remains below the 5.0× covenant but offers little cushion if EBITDA falls further. Management has frozen discretionary cash uses until leverage dips below 3.5×.
What could improve sentiment in the next 12 months?
Key drivers would be tariff relief, visible traction on cost savings, stabilisation in Beauty & Wellness demand, and leverage reduction through stronger cash generation or asset sales.
